Early nutritional screening may benefit patients receiving vismodegib

the ONA take:

Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib, a new study published online ahead of print in the journal Supportive Care in Cancer has suggested.

Although vismodegib is effective in the treatment of this type of skin cancer, weight loss and dysgeusia (persistent abnormal taste or change in taste) are common treatment-related adverse events.

Therefore, researchers sought to monitor the nutritional status of vismodegib-treated patients, as well as assess the incidence of dysgeusia and the benefit of early nutritional management.

For the prospective study, researchers enrolled 45 patients with locally advanced or metastatic basal cell carcinoma who started vismodegib between October 2011 and May 2013 at Nantes University Hospital in France. 

Of those, 24 patients had not received any specific nutritional management while 21 patients were evaluated by a physician from the Nutrition Support Unit and received dietary counseling at the time of vismodegib initiation.

Results showed that 24% of patients receiving dietary counseling were undernourished at vismodegib initiation and the 6-month cumulative incidence of dysgeusia was 71%.

Researchers found that 38% of patients receiving dietary counseling experienced a weight loss greater than 5% compared with 54% of those who did not receive any specific nutritional management.

“The potential benefit of nutritional support in this setting warrants further investigation,” the authors conclude.

Early nutritional screening may benefit patients receiving vismodegib
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib.
Whereas vismodegib is effective in the treatment of locally advanced/metastatic basal cell carcinoma, dysgeusia and weight loss are common side effects of such treatment. The main objective of this study was to monitor the nutritional status of vismodegib-treated patients. Secondary objective was to assess the incidence of dysgeusia and the benefit of early nutritional management.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs